Evidence map›Paper›PMID 42630541›Full record

ArticleFrontiers in immunology2026

SHAP-interpretable machine learning integrating exposures and multi-omics reveals immune alterations and biomarkers in COPD-lung cancer comorbidity.

Yiran Fei, Yinying Chai, Shiyuan Tong, Bohao Sun, Ziqiang Chen, Shiliang Chen, Zhezhong Zhang, Yibo He, Shengliang Qiu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiran Fei *The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Yinying Chai *The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Shiyuan TongState Key Laboratory of Medical Neurobiology and Ministry of Education (MOE) Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, China.
Bohao SunDepartment of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Ziqiang ChenEar, Nose, and Throat (ENT) Institute and Department of Otorhinolaryngology, Eye and ENT Hospital, Fudan University, Shanghai, China.
Shiliang ChenThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Zhezhong ZhangThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Yibo HeThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Shengliang QiuThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) frequently co-occur and share environmental and biological determinants, yet their cross-scale associations remain incompletely understood. Artificial intelligence and machine learning-based integration of exposome and multi-omics data provide new opportunities for dissecting this complex comorbidity. Methods: This study established a sequential, cross-scale framework integrating global epidemiological analysis of GBD data (1990-2021), exposome-wide risk factor assessment using random forest classification with SHAP interpretation, immune microenvironment characterization via CIBERSORT and single-cell RNA sequencing with LLM-assisted annotation, candidate gene prioritization through SMR analysis, LASSO regression, and machine learning classifiers, and experimental validation using RT-qPCR, western blotting, immunohistochemistry, dual immunofluorescence, and macrophage-epithelial Transwell co-culture. Results: COPD and LC demonstrated persistent global co-occurrence patterns across 204 countries and territories. SHAP analysis identified smoking, particulate matter pollution, and residential radon as major shared risk factors. Bulk and single-cell transcriptomic analyses revealed consistent immune microenvironment remodeling, with macrophages as the predominant shared immune population. Multi-omics intersection and machine learning prioritization identified TREM1 and ODF2L as shared hub genes, significantly downregulated in COPD and LC tissues. Macrophage-specific silencing of TREM1 or ODF2L attenuated macrophage-mediated promotion of A549 cell migration and proliferation, and dual immunofluorescence confirmed macrophage-associated localization of both proteins. Discussion: These findings provide a cross-scale perspective linking environmental exposures, macrophage-centered immune alterations, and COPD-LC comorbidity. TREM1 and ODF2L represent promising macrophage-associated candidate biomarkers and potential therapeutic targets. Integrating interpretable machine learning with exposome and multi-omics data offers a robust framework for biomarker discovery in chronic respiratory disease comorbidity.

Indexed as

Lung NeoplasmsMachine LearningPulmonary Disease, Chronic ObstructiveBiomarkersBiomarkers, TumorComorbidityEnvironmental ExposureHumansMultiomicsRisk FactorsTumor MicroenvironmentBiomarkersBiomarkers, Tumorartificial intelligence (AI)chronic obstructive pulmonary disease (COPD)immune microenvironmentlung cancermulti-omics integration

Identifiers

PMID42630541
PMCPMC13494581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.